1334541-15-9

Basic information

• Product Name: methyl (1R,2S)-2-(2-cyanoethyl)-1-(1-phenyl-1H-imidazol-4-yl)cyclopropane carboxylate
• Synonyms: methyl (1R,2S)-2-(2-cyanoethyl)-1-(1-phenyl-1H-imidazol-4-yl)cyclopropane carboxylate
• CAS NO: 1334541-15-9
• Molecular Weight: 295.341
• Mol File: 1334541-15-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl (1R,2S)-2-(2-cyanoethyl)-1-(1-phenyl-1H-imidazol-4-yl)cyclopropane carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (1R,2S)-2-(2-cyanoethyl)-1-(1-phenyl-1H-imidazol-4-yl)cyclopropane carboxylate(1334541-15-9)
• EPA Substance Registry System: methyl (1R,2S)-2-(2-cyanoethyl)-1-(1-phenyl-1H-imidazol-4-yl)cyclopropane carboxylate(1334541-15-9)

Safety Data

• Hazardous Substances Data: 1334541-15-9(Hazardous Substances Data)

Upstream product

• 18502-05-1 4-cyanomethylimidazole 
• 98-80-6 phenylboronic acid 
• 1334541-10-4 (1-phenyl-1H-imidazol-4-yl)acetonitrile 
• 1334541-11-5 (1R,5S)-1-(1-phenyl-1H-imidazol-4-yl)-3-oxabicyclo[3.1.0]hexan-2-one 

Downstream Products

• 1334541-16-0 methyl (1R,2S)-2-{3-[(tert-butoxycarbonyl)amino]propyl}-1-(1-phenyl-1H-imidazol-4-yl)cyclopropane carboxylate 

Relevant articles and documents

CYCLOPROPANECARBOXYLIC ACID DERIVATIVE

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.